ACET · Adicet Bio, Inc. · Executive Compensation
$2.93
-0.06 (-2.01%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, our outstanding and future payment obligations, and the potential need to raise additional capital to finance our future operations, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period at least twelve months from the date of issuance of these unaudited consolidated financial statements.”View the 10-Q filed Nov 5, 2026
Market Cap
$27.43M
Shares
9.36M
Volume · Nov 12
371.41K
Avg daily vol (3M)
226.86K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $1,465,747 |
| Julia Maltzman | Chief Medical Officer | $1,124,803 |
| Blake Aftab | Chief Scientific Officer and Senior Vice President | $915,489 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $4,644,365 |
| Francesco Galimi | M.D., Ph.D. Former Chief Medical Officer | $1,847,772 |
| Nick Harvey | Chief Financial Officer | $1,523,426 |
| Blake Aftab | Chief Scientific Officer and Senior Vice President | $1,473,576 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $5,973,807 |
| Nick Harvey | Chief Financial Officer | $2,132,688 |
| Donald Healey | Chief Technology Officer | $2,089,460 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $3,988,018 |
| Blake Aftab | Chief Scientific Officer | $2,479,544 |
| Francesco Galimi | Chief Medical Officer | $1,989,027 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $9,756,998 |
| Nick Harvey | Chief Financial Officer | $2,379,030 |
| Francesco Galimi | Chief Medical Officer | $2,340,860 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $11,276,287 |
| Lloyd Klickstein | M.D., Ph.D.^(^ ^)^ Chief Innovation Officer | $2,897,351 |
| Francesco Galimi | Chief Technology Officer | $1,527,789 |
| Anil Singhal | Ph.D. ^(^^8)^ Chief Executive Officer | $1,404,520 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $2,778,243 |
| Anil Singhal | Ph.D. ^(^^8)^ Chief Executive Officer | $2,703,931 |
| Lloyd Klickstein | M.D., Ph.D.^(^ ^)^ Chief Innovation Officer | $2,415,323 |
| Joan Mannick | Chief Medical Officer | $1,364,863 |
| Francesco Galimi | M.D., Ph.D.^(1^ ^)^ Chief Medical Officer | $659,750 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Chen Schor | President and Chief Executive Officer | $3,094,901 |
| Joan Mannick | Chief Medical Officer | $1,452,992 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Grissinger | Class II director | Appointed | 2025-04-17 |
| Carl L. Gordon | Class II member of the board of directors | Resigned | 2025-04-17 |
| Lloyd Klickstein, M.D., Ph.D. | Class III director | Appointed | 2024-08-19 |
| Michael Kauffman, M.D., Ph.D. | Class III member of the board of directors | Resigned | 2024-08-19 |
| Andrew Sinclair, Ph.D. | Class III Director | Appointed | 2024-06-07 |
| Michael G. Kauffman, M.D., Ph.D. | Class III Director | Appointed | 2024-06-07 |
| Katie Peng | member of the Audit Committee | Appointed | 2023-11-13 |
| Bastiano Sanna, Ph.D. | Class III member of the Board of Directors | Resigned | 2023-11-13 |
| Katie Peng | Class I director | Appointed | 2023-07-11 |
| Jeffrey Chodakewitz | Class II director | Appointed | 2023-06-05 |
| Steve Dubin | Class II director | Appointed | 2023-06-05 |
| Carl L. Gordon | Class II director | Appointed | 2023-06-05 |
Leadership
- Chen Schor CEO
- Nick Harvey CFO
- Stewart Abbot COO
- Stewart Abbot, Ph.D. COO
- Don Healey, Ph.D. CTO
- Donald Healey CTO
- Lloyd Klickstein CIO
- Andrew Sinclair, Ph.D. Board Member
- Carl Gordon Board Member
- Carl L. Gordon Board Member
- Carl L. Gordon, Ph.D. Board Member
- Erez Chimovits Board Member
- Jeffrey Chodakewitz Board Member
- Jeffrey Chodakewitz, M.D. Board Member
- Lloyd Klickstein, M.D., Ph.D. Board Member
- Michael G. Kauffman, M.D., Ph.D. Board Member
- Michael Grissinger Board Member
- Steve Dubin Board Member
- Yair Schindel Board Member
Key facts
CIK
1720580
CUSIP
007002207
13F (30d)
37 filings
25 filers
Visit website
Investor relations